1. The combination of anti-MIF antibodies with glucocorticoids for use in the treatment of glucocorticoid-susceptible diseases. The combination of claim 1, wherein the glucocorticoid-susceptible disease responds to glucocorticoid treatment. 3. The combination according to claim 1 or 2 for use in the treatment of inflammation, allergies, cancer or asthma. 4. The combination of claim 1 or 2, wherein the antibody is an anti-oxMIF antibody. The combination according to claim 1 or 2, wherein the anti-MIF antibody is selected from the following group: anti-MIF antibody RAB9, RAB4, RAB0, RAM9, RAM4 and / or RAM0.6. The combination according to claim 1 or 2, wherein the glucocorticoid is selected from the group consisting of glucocorticoid receptor agonists, for example, methylprednisolone, prednisolone, triamcinolone, dexamethasone, parametasone, fluorocortolone, budesonide, fluticasone, flunisolide, cyclonezonazone, coronazonazone, coronazone and anti-inflammatory SEGRA / SEGRM (e.g. Mapracorat (= BOL303242X = ZK245186), compound, RU 24856, RU 24782, RU 40066, ZK 216348) .7. The combination of claim 1 or 2, wherein the anti-MIF antibody is one of RAB9, RAB4, or RAB0, or RAM9, RAM4 or RAMO, preferably a RAM9 antibody, wherein the glucocorticoid is selected from the group in which (methyl) prednisone and dexamethasone for systemic administration, and budesonide for local administration, and the MIF-associated disease is inflammation, in particular nephritis, even more preferably lupus nephritis, glomerulonephritis, IgA or IgM nephropathy, systemic vasculitis (e.g. nodular polyarteritis, Wegen granulomatosis ra and purpura of Schönlein-Genoch), anti-GBM nephritis and / or rapidly progressive glomerulonephritis, (type I, II, III or IV), for example, nephritis with anti-neutrophilic cytoplasmic antibodies (ANCA-nephritis) .8. The combination of claim 1 or 2, wherein the anti-MIF antibody is one1. Комбинация анти-MIF-антитела с глюкокортикоидами для применения в лечении глюкоко
